临床前资产市场：按服务、模型类型、最终用户和地区划分

2026年临床前资产市场规模估计为68亿美元，预计2033年将达到92亿美元。预计2026年至2033年，该市场将以8.6%的复合年增长率成长。

临床前资产涵盖多种服务，例如生物分析和药物代谢及药物动力学 (DMPK) 测试。这些服务还包括基于良好实验室规范 (GLP) 和非 GLP 的体外和体内分析、毒性测试、化合物管理流程、研发 (R&D)、合约合成、对掌性合成以及其他服务（放大生产、cGMP、安全性药理学）。临床前资产包括两种类型的模型：患者来源的类器官 (PDO) 模型和患者来源的异种移植模型。

市场动态

预计在预测期内，主要市场公司不断推出临床前试验服务将推动全球临床前资产市场成长。例如，2020年7月，化妆品公司Skinobs宣布推出其新的临床前试验平台“skinobs”，这是一个独立的工具，可提供体内疗效测试的360度全方位观点。该平台允许用户根据各种标准识别和选择试验方法，例如：

• 测试类别包括：分析测试、组件和容器相互作用测试、生态毒性和生物降解性测试、安全测试、紫外线测试等。
• 功效包括抗衰老和抗污染。
• 测试支持包括细胞培养、3D皮肤模型等。

同样，2021年12月，软体公司Sirona Medical在北美放射学会（RSNA）2021年年会上宣布推出其云端原生放射学作业系统（RadOS）。该平台基于技术和人工智慧的融合，旨在帮助医生在临床环境中提升决策能力。

本研究的主要特点：

• 本报告详细分析了全球临床前资产市场、市场规模以及 2026 年至 2033 年预测期内的复合年增长率 (%)，其中 2025 年为基准年。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业所采取的竞争策略的关键见解。
• 本报告根据以下参数对全球临床前资产市场的主要企业进行了分析：公司概况、财务表现、产品系列、地理企业发展、分销策略、关键发展和整体策略。
• 透过利用本报告中的见解，企业负责人和经营团队可以就未来的产品发布、政府主导的倡议、技术升级、市场扩张和行销策略做出明智的决策。
• 这份全球临床前资产市场报告的目标受众包括行业内的各类相关人员，例如投资者、产品製造商、经销商、供应商、研究和咨询公司、新参与企业和金融分析师。
• 相关人员可以透过利用分析全球临床前资产市场中使用的各种策略矩阵来简化决策过程。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 抑制因子
  • 市场机会
• 影响分析
• 市场趋势
• 主要进展
• 技术进步
• 监理情势
• PEST分析

第四章 全球临床前资产市场：依服务类型划分，2026-2033年

• 概述
• 生物分析和DMPK测试
• 毒性测试
• 化合物管理
• 安全药理学
• 其他（化学等）

第五章 全球临床前资产市场：依模型类型划分，2026-2033年

• 概述
• 患者来源的类器官（PDO）模型
• 患者来源的异种移植模型

第六章 全球临床前资产市场：依最终使用者划分，2026-2033年

• 概述
• 生物製药公司
• 政府机构
• 其他（学术和研究机构）

第七章 全球临床前资产市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 北非
  • 中非
  • 南非

第八章 竞争情势

• 热图分析
• 公司简介
  • Eurofins Scientific
  • ICON plc
  • WuXi AppTec
  • Viroclinics Xplore
  • Medpace, Inc.
  • Charles River Laboratories.
  • Pharmatest Services
  • PPD Inc.
  • SGS SA（SGS）
  • Intertek Group plc
  • Labcorp Drug Development
  • Laboratory Corporation of America, Inc.
  • Crown Bioscience
  • Comparative Biosciences, Inc.
  • TCG Lifesciences Private Limited.
  • Shanghai Medicilon Inc.
  • Domainex
  • Absorption Systems
  • AmplifyBio
  • IQVIA

第九章

• 参考
• 调查方法
• 关于本公司

Preclinical Assets Market is estimated to be valued at USD 6.8 Bn in 2026 and is expected to reach USD 9.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.

Preclinical assets consist of various types of services such as Bioanalysis and DMPK (Drug Metabolism and pharmacokinetics) studies, which are further sub segmented into in vitro and in vivo analysis, toxicology testing, which are based on GLP and non GLP (Good Laboratory Practices), compound management process R&D (Research and development), custom synthesis, asymmetric synthesis, and others (Scale-up, cGMP (current good manufacturing practices), safety pharmacology). Preclinical assets have two types of models, patient derived organoid (PDO) model and patient derived xenograft model.

Market Dynamics

Increasing number of service launch in preclinical testing by the key market players is expected to drive growth of the global preclinical assets market during the forecast period. For instance, in July 2020, Skinobs, a cosmetic company, announced the launch of a new preclinical testing platform skinobs, an independent tool which provides a 360-degree vision of in vivo efficacy testing. This platform enables users to identify and select the testing methods depending on various criteria such as

• Test Category: which include analytical tests, content-contenair interaction, ecotoxicity and biodegradability tests, safety tests, UV (Ultra Violet ) tests, etc.
• Claim: which include anti-ageing, anti-pollution, etc.
• Test support: which include cell cultures, 3D skin models, etc.

Similarly, in December 2021, Sirona Medical, a software company, announced the launch of its cloud-native radiology operating system (RadOS) optimizing the use of novel AI (Artificial Intelligence) applications in clinical practice at the 2021 Annual Meeting for Radiological Society of North America (RSNA). The platform was based on the combination of technology and artificial intelligence, which would help augment the intelligence of the physician in clinical practices.

Key features of the study:

• This report provides an in-depth analysis of the global preclinical assets market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global preclinical assets market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global preclinical assets market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preclinical assets market

Market Segmentation

• By Service
  • Bioanalysis and DMPK studies
  • In vitro
  • In-vivo
  • Toxicology Testing
  • GLP
  • Non-GLP
  • compound management
  • Process R&D
  • Custom Synthesis
  • Asymmetric Synthesis & Others (Scale-up, cGMP, etc.)
  • Safety Pharmacology
  • Others (Chemistry, etc.)
• By Model type
  • Patient Derived Organoid (PDO) Model
  • Patient derived xenograft model
• By End user
  • Biopharmaceutical Companies
  • Government Institutes
  • Others (Academic and Research institutes)
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Eurofins Scientific
  • ICON plc
  • WuXi AppTec
  • Viroclinics Xplore
  • Medpace, Inc.
  • Charles River Laboratories.
  • Pharmatest Services
  • PPD Inc.
  • SGS SA (SGS)
  • Intertek Group plc
  • Labcorp Drug Development
  • Laboratory Corporation of America, Inc.
  • Crown Bioscience
  • Comparative Biosciences, Inc.
  • TCG Lifesciences Private Limited.
  • Shanghai Medicilon Inc.
  • Domainex
  • Absorption Systems
  • AmplifyBio
  • IQVIA

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Service
  • Market Snapshot, By Model Type
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Technological Advancements
• Regulatory Landscape
• PEST Analysis

4. Global Preclinical Assets Market, By Service, 2026 - 2033, (USD Bn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Bioanalysis and DMPK studies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • In vitro
    • In-vivo
• Toxicology Testing
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • GLP
    • Non-GLP
• Compound Management
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Process R&D
    • Custom Synthesis
    • Asymmetric Synthesis
    • Others (Scale-up and cGMP)
• Safety Pharmacology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others (Chemistry, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Preclinical Assets Market, By Model Type, 2026 - 2033, (USD Bn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Patient Derived Organoid (PDO) Model
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Patient derived xenograft model
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Preclinical Assets Market, By End User, 2026 - 2033, (USD Bn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Biopharmaceutical Companies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Government Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others (Academic and Research institutes)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Preclinical Assets Market, By Region, 2026 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Eurofins Scientific
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • ICON plc
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • WuXi AppTec
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Viroclinics Xplore
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Medpace, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Charles River Laboratories.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Pharmatest Services
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • PPD Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • SGS SA (SGS)
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Intertek Group plc
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Labcorp Drug Development
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Laboratory Corporation of America, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Crown Bioscience
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Comparative Biosciences, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • TCG Lifesciences Private Limited.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Shanghai Medicilon Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Domainex
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Absorption Systems
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • AmplifyBio
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • IQVIA
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us